ClinicalTrials.gg
RecruitingNCT07428746GLOWUpdated Aug 3, 2026

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

A Phase 3 interventional study of Semaglutide in Diabetes Mellitus, Type 2, sponsored by Emory University. Recruiting at 1 site in United States. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Emory University · Phase 3, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
65 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Planned enrollment
150th of 163
20 · median 104
Started
2026
with 7 others
Phase 3
57 of 163
7 open now
Primary completion
2028-11
later than 40 of 44 live
Registered
158th of 163
by date

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 150th largest by planned enrollment, is one of 8 that started in 2026, is one of 57 in phase 3, reaches primary completion later than 40 of the 44 other live ones, and was the 158th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

29 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 65 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes.

The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength.

Participants will:

  • Receive GLP-1 RA therapy as part of their routine clinical care
  • Complete muscle strength assessments (hand grip strength, Timed Up and Go test)
  • Provide blood samples for bone turnover markers
  • Undergo bone mineral density testing
Read the detailed description

Older females with type 2 diabetes experience a disproportionately high burden of osteosarcopenia, a condition defined by the coexistence of low muscle mass, reduced muscle strength, and decreased bone mineral density. Osteosarcopenia is associated with increased risks of falls, fractures, functional decline, hospitalization, and loss of independence. Diabetes contributes to these risks through multiple mechanisms, including impaired bone microarchitecture, reduced muscle quality, neuropathy-related balance disturbances, and chronic inflammation. These effects are amplified in older women, who already experience age-related declines in muscle and bone health following menopause.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, are widely used for glycemic management and weight reduction in type 2 diabetes. While these medications provide substantial metabolic benefits, clinical studies have reported that weight loss associated with GLP-1 RA therapy may include reductions in lean body mass. The implications of these changes for muscle strength, bone turnover, and bone mineral density remain unclear, particularly in older females with type 2 diabetes who may be more vulnerable to muscle and bone loss. Existing data on GLP-1 RAs and fracture risk are limited and inconsistent, and most prior studies have evaluated older, less potent agents with minimal weight-loss effects.

This prospective observational study is designed to characterize changes in muscle and bone health during 6 months of GLP-1 RA therapy in older females with type 2 diabetes who are receiving treatment as part of routine clinical care. The study will enroll 20 women over the age of 65. Participants will undergo standardized assessments of muscle strength, bone turnover markers, and bone mineral density at baseline and follow-up. Muscle strength will be evaluated using validated functional measures, and bone health will be assessed through laboratory markers of bone remodeling and imaging-based measures of bone density.

The study does not alter clinical treatment decisions; GLP-1 RA therapy is prescribed independently by participants' healthcare providers based on FDA-approved indications. Study procedures focus on evaluating physiological changes associated with treatment in a population at elevated risk for osteosarcopenia. Data collected will help clarify whether GLP-1 RA therapy influences muscle strength, bone turnover, or bone mineral density in older females with type 2 diabetes. Findings may inform future strategies to support musculoskeletal health in this growing and medically vulnerable population.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • GLP-1 Receptor analogs
  • Semaglutide
  • DEXA
  • Osteosarcopenia
  • Bone Mineral Density
  • Bone turnover markers
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women aged 65 years or older
  • Has type 2 diabetes
  • (BMI) ≥27 kg/m² to max 40kg/m2 (inclusive)
  • >7% within 3 months of the first visit.
  • Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.
  • No osteoporosis confirmed on DEXA scan within 12 months
  • Able to provide and participate in all study assessments

Exclusion criteria

Exclusion Criteria:

  • Patients with type 1 diabetes mellitus or other types of diabetes that are not T2D
  • \<30 ml/min in the last 3 months
  • Patients with a history of treatment with anti-osteoporosis agents
  • Documented primary or secondary osteoporosis on a DEXA scan within the last 12 months, or are on osteoporosis therapies
  • Documented presence of prosthesis or devices in the spine or hip
  • Previous fragility fracture
  • Males
  • Moderate to severe gastroesophageal reflux disease based on patient history.
  • Inability to comply with the treatment protocol or to understand the consent form.
  • (AST) > 3 times normal or alanine aminotransferase (ALT) > 3 times the normal
  • Subjects with uncontrolled thyroid or parathyroid disease that may influence the study results.
  • Personal or family history of medullary thyroid carcinoma.
  • Personal or family history of multiple endocrine neoplasia type 2 syndrome.
  • Personal history of gastroparesis, celiac disease, hypogonadism, severe , hypopituitarism, or Cushing's disease
  • Personal history of severe diabetic retinopathy.
  • Known serious , including anaphylaxis and angioedema, to semaglutide or any of its .
  • Any of the following drugs or treatments were used within 6 months before screening: treated with GLP-1RA, GIP analogues, pioglitazones
  • Concomitant treatment with GLP-1 receptor agonist therapy
  • Long-term intravenous, oral, and intra-articular administration of high-dose within 2 months before screening (more than 7 days in a row)
  • Use of weight control drugs or surgery that can lead to weight changes during the last 6 months before screening, or are currently in the weight loss plan and are not in the maintenance stage
  • Incarcerated individuals
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Type 2 Diabetics on Semaglutide

    Participants will receive a GLP-1 receptor agonist (GLP-1 RA) prescribed as part of their routine clinical care. Dosing will follow standard clinical practice and will be titrated to each participant's maximum tolerated dose. The study will observe metabolic, musculoskeletal, and functional changes associated with ongoing GLP-1 RA therapy over a 6-month period.

    Drug: Semaglutide

Interventions

  • Semaglutide is an FDA-approved drug for the treatment of T2D at the following doses (0.25, 0.5, 1, and 2 mg) that is self-administered weekly using an autoinjector pen. The drug dosage will gradually increase every 4 weeks if tolerated to reach maintenance doses of 2 mg for semaglutide until the end of the study (6 months). If a participant cannot tolerate a dose, the highest tolerable dose will be administered, with continued efforts to increase the dose over time, gradually.

    Also known as: GLP 1 RA

06

What researchers measure

Primary outcomes

  1. Change in handgrip strength

    Handgrip strength is a validated indicator of overall muscle strength and a core diagnostic component of sarcopenia. HGS will be assessed using a calibrated hydraulic hand dynamometer. Output is recorded in kilograms (kg) of force. Higher values indicate greater muscle strength

    Time frame: Baseline, week4, week 8, week12, week 26.

Secondary outcomes

  1. Change in bone turnover markers

    Bone turnover markers (BTMs) reflect the rate of bone remodeling, including both bone formation and bone resorption processes. These laboratory biomarkers provide insight into dynamic skeletal changes that may occur during GLP-1 receptor agonist therapy. BTMs may include: * Bone formation markers (e.g., P1NP) * Bone resorption markers (e.g., CTX) Results will be reported in standard laboratory units (e.g., ng/mL, µg/L), depending on the specific assay. Higher formation markers indicate increased bone formation; higher resorption markers indicate increased bone breakdown

    Time frame: Baseline, 3 month, 6 months

  2. Change in timed up-and-go (TUG)

    The Timed Up and Go (TUG) test assesses functional mobility by measuring the time required for a participant to rise from a standard chair, walk to a marked 10-foot line, turn around, return to the chair, and sit down. Time is recorded in seconds (s). * Shorter times indicate better functional mobility. * Longer times may reflect impairments in balance, gait speed, or lower-extremity strength.

    Time frame: Baseline, week4, week 8, week12, week 26.

  3. Change in HbA1c

    Collected via venous blood sample and analyzed using standardized laboratory assays. HbA1c will be reported as a percentage (%). Reductions in HbA1c and fasting glucose reflect improved insulin sensitivity and glycemic regulation.

    Time frame: Baseline, 3 month, 6 months

  4. Change in fasting glucose

    Measured after an overnight fast of at least 8 hours. Fasting glucose will be reported in mg/dL. Reductions in fasting glucose reflect improved insulin sensitivity and glycemic regulation

    Time frame: Baseline, 6 months

  5. Change in weight

    Measured using a calibrated digital scale with participants wearing light clothing and no shoes. Body weight will be reported in kilograms (kg). Weight change (kg) will be calculated as the difference between baseline and follow-up measurements

    Time frame: Baseline, week4, week 8, week12, week 26.

  6. Change in FRAX score

    Fracture risk will be evaluated using the FRAX algorithm, which integrates bone mineral density (BMD) at the femoral neck with validated clinical risk factors to estimate the 10-year probability of major osteoporotic fracture and hip fracture. FRAX results are expressed as percent probabilities (%). Lower percentages indicate reduced fracture risk.

    Time frame: Baseline, 6 months

  7. Change in lipid profile

    Serial lipid measurements will be collected to evaluate cardiovascular risk modification during GLP-1 receptor agonist therapy. LDL-C, HDL-C, triglycerides, and total cholesterol will be reported in mg/dL. * Change in each lipid parameter will be calculated as the difference between baseline and 6-month values. * Lower LDL-C and triglycerides, along with higher HDL-C, indicate improved cardiovascular risk profiles.

    Time frame: Baseline, 3 months, 6 months

  8. Changes in exercise frequency

    The Community Healthy Activities Model Program for Seniors (CHAMPS) Physical Activity Questionnaire is a validated self-report tool designed to assess weekly frequency and duration of lifestyle physical activities commonly performed by older adults. It captures a broad range of activities across light, moderate, and vigorous intensities, providing a comprehensive estimate of habitual physical activity. Responses are used to calculate the total weekly frequency of various activity categories. Weekly frequency of each activity (number of sessions per week)

    Time frame: Baseline, 6 months

  9. Changes in exercise duration

    The Community Healthy Activities Model Program for Seniors (CHAMPS) Physical Activity Questionnaire is a validated self-report tool designed to assess weekly frequency and duration of lifestyle physical activities commonly performed by older adults. It captures a broad range of activities across light, moderate, and vigorous intensities, providing a comprehensive estimate of habitual physical activity. Responses are used to calculate the total weekly duration of various activity categories. Higher values indicate greater physical activity engagement.

    Time frame: Baseline, 6 months

  10. Change in frailty assessment

    Frailty will be assessed using a questionnaire based on the Fried phenotype, evaluating five components: unintentional weight loss, exhaustion, low physical activity, slowness, and weakness. A structured data capture form modeled on the validated assessment will be used. Assessment Procedure \& Scoring: * Completed at baseline and 6 months. * Each criterion is scored as present or absent (0-5 total). * 0: Non-frail * 1-2: Pre-frail * ≥3: Frail Interpretation: Higher scores indicate greater frailty; changes over time reflect shifts in physiologic vulnerability.

    Time frame: Baseline, 6 months

Other outcomes

  1. Change in bone mineral density

    Bone mineral density will be assessed using dual-energy X-ray absorptiometry (DEXA). Imaging will be performed at the femoral neck, total hip, and lumbar spine, which are standard anatomical sites for evaluating osteoporosis and fracture risk. BMD will be reported in grams per square centimeter (g/cm²). Z-scores reflect how a participant's bone density compares with expected values for individuals of the same demographic profile. Lower Z-scores may indicate reduced bone density and increased susceptibility to osteopenia or osteoporosis.

    Time frame: Baseline, 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2028, 30 months after the start.

Of 87 non-industry phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 30 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Feb 24, 2026
StartActual
May 7, 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07428746
Lead sponsor
Emory University
Responsible party
Thaer Idrees (Assistant Professor, Emory University) — Principal investigator
First posted
Feb 24, 2026
Start date
May 7, 2026
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Aug 3, 2026

Study contacts

Thaer Idrees, MD, FSSCI
Contact
thaer.idrees@emory.edu
404-251-5357
Jaafer Zaino
Contact
jaafer.zaino@emory.edu
Thaer Idrees, MD, FSSCI
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion